BioNTech to present clinical & pre-clinical data from mRNA and next-generation immuno-oncology priority programmes at ...
BioNTech SE will be presenting data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (AACR) 2025 …